

DAYBUE™ (trofinetide) Prescription and Enrollment Form Overview

A helpful guide for completing and submitting DAYBUE prescriptions



The **Prescription and Enrollment Form** is used to prescribe DAYBUE to patients **AND** have parents/legal guardians provide consent to enroll their loved one in the Acadia Connect® patient and family support program’s full suite of services.


Review all sections of the **Prescription and Enrollment Form**.

The prescribing physician (or office staff) and the patient’s parent/legal guardian should complete and sign where indicated.


Fax or email the completed form to Acadia Connect at **1-888-385-2748** or **DAYBUE@AcadiaConnect.com**.

You will receive a receipt of enrollment and a Nurse Care Coordinator will reach out within 24 hours.

Completing Page 1 Patient and Parent/Legal Guardian Information



PRESCRIPTION AND ENROLLMENT FORM



Healthcare providers:

- Please submit completed enrollment form, copy of all insurance cards (front and back), and copy of patient’s clinical chart notes to Acadia Connect®
- Have the parent/legal guardian read Section 8 and sign where indicated
- Fax the completed form to Acadia Connect at 1-888-385-2748
- If your office has not received a confirmation fax that your enrollment form has been received within one (1) business day after submission, please resubmit or call Acadia Connect at 1-844-737-2223, Monday to Friday, 8AM to 8PM ET

1 PATIENT AND PARENT/LEGAL GUARDIAN INFORMATION

PATIENT INFORMATION

Please select one: Newly Prescribed Patient Clinical Trial Patient Clinical Trial ID #: _____

First Name: _____ Middle Initial: _____ Last Name: _____

Address: _____ City: _____ State: _____ ZIP Code: _____

Date of Birth (MM/DD/YYYY): _____ Gender: _____

PARENT/LEGAL GUARDIAN INFORMATION

First Name: _____ Last Name: _____

Relationship to Patient: _____ Preferred Language: English Spanish Other _____

Home Phone #: _____ Mobile Phone #: _____

Work Phone #: _____ Preferred Phone #: Home Work Mobile

Best Time to Call: Morning Afternoon Evening Can We Leave a Message? Yes No

Email Address: _____

2 INSURANCE INFORMATION No insurance

Primary Medical Insurance Name: _____

Policy #: _____ Group #: _____ Phone #: _____

Policy Holder’s Full Name: _____

Date of Birth (MM/DD/YYYY): _____ Relationship to Patient: _____

Prescription Drug Insurance Name: _____ Rx Phone #: _____

Rx Group #: _____ Rx PCN #: _____ Rx BIN #: _____

Secondary Medical Insurance Name: _____

Policy #: _____ Group #: _____ Phone #: _____

Policy Holder’s Full Name: _____

Date of Birth (MM/DD/YYYY): _____ Relationship to Patient: _____

Prescription Drug Insurance Name: _____ Rx Phone #: _____

Rx Group #: _____ Rx PCN #: _____ Rx BIN #: _____

3 ADDITIONAL CARE TEAM INFORMATION (eg, neurologist, physical therapist, school nurse, pediatrician, gastroenterologist)

By providing this information, I certify that I have permission from the following care team members to disclose their personally identifiable information to, and be contacted by, Acadia Pharmaceuticals Inc. (including its representatives and agents) for the purpose of supporting the patient’s care and treatment on DAYBUE™ (trofinetide).

CARE TEAM ROLE	NAME	EMAIL	PHONE

1 of 3

A

Instructions for submitting the form to Acadia Connect.

B

Check the appropriate box identifying the patient as either a “Newly Prescribed Patient” or a “Clinical Trial Patient.” If applicable, include the “Clinical Trial ID #” where indicated.

C

If the patient is covered under both medical and pharmacy insurance, and/or has any secondary medical insurance, include information for all applicable plans. Having this information upfront can help complete the benefits investigation in a timely manner.

D

The parent/legal guardian and prescribing physician/office staff should list the names and contact information for any other healthcare providers that may be part of the patient’s care team. Examples include a neurologist, physical therapist, school nurse, pediatrician, or gastroenterologist.

Completing Page 2

Prescriber, Clinical, and Prescription Information





PRESCRIPTION AND ENROLLMENT FORM



Patient's Name: _____ Date of Birth (MM/DD/YYYY): _____

4 PRESCRIBER INFORMATION

Prescriber First Name: _____ Last Name: _____
 Prescriber Specialty: _____ Practice Name: _____
 Address: _____ City: _____ State: _____ ZIP Code: _____
 NPI #: _____ Medical Provider ID #: _____ DEA #: _____
 Phone #: _____ Fax #: _____
 Office Contact: _____ Contact Phone #: _____ Contact Email: _____

5 CLINICAL INFORMATION

Applicable ICD-10 Code: _____ Has the Patient Had Genetic Testing? Yes No Date of Test: _____
(methyl-CpG binding protein 2 [MECP2])
 Genetic Test Company: _____
 Genetic Test Results: _____

6 PHARMACY PRESCRIPTION

Drug: DAYBUE™ (trofinetide) 200 mg/mL, Oral Solution Prescribing Directions: Take _____ mL Twice Daily Day Supply: _____ Refills: _____
 Patient's Weight (kg): _____ Administration: Oral Gastrostomy Tube Type: NeoMed® Oral Dispenser ENFit® Luer Lock Syringe
 Additional Prescribing Directions: _____
 Patient's Allergies: NKDA Please List: _____
 Current Medications: _____
In their monthly shipments, all patients will receive ancillary materials required for the treatment method selected by the prescriber.

7 PRESCRIBER AUTHORIZATION

I attest that I have obtained written permission, in the event it is required under applicable federal and/or state law, of my patient (or the patient's legal representative) for the release of my patient's Protected Health Information ("PHI") to Acadia Pharmaceuticals Inc. or its representatives or agents (collectively "Acadia") as may be necessary for the patient's participation in a program designed to assist patients in determining their insurance coverage for DAYBUE that I have elected to prescribe. I direct Acadia to convey, on my behalf, any prescription-related PHI and other prescribing information delivered to Acadia for DAYBUE to the dispensing pharmacy chosen by or for the patient, to the patient's health insurance company, and to other third parties as may be necessary for dispensing the patient's prescription for DAYBUE, with verifying the patient's insurance coverage for DAYBUE, providing information regarding payer coverage and benefits and how to prepare prior authorization requests, coverage determination appeals, or other coverage issues, and/or assisting with patient assistance and support or reduced-cost DAYBUE. I understand I am to comply with the state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. I agree that Acadia may contact me for additional information relating to DAYBUE, including but not limited to via email, fax, and telephone. I appoint Acadia as my agent for the purpose of conveying this prescription to the appropriate dispensing pharmacy. I certify that DAYBUE is medically necessary and in the best interest of the named patient.

My signature below certifies that I have read, understand, and agree to the Prescriber Authorization statement above.

Sign Here Signature (Dispense as Written): _____ No Stamp Signature _____ Date: _____
OR
Sign Here Signature (Substitution Allowed): _____ No Stamp Signature _____ Date: _____
 Print Name: _____

2 of 3

E

Include the patient's name and date of birth (DOB) at the top of every page.

F

Note whether the patient has undergone genetic testing and include all related genetic testing information where indicated.

G

Provide the prescribing directions, including the weight-based dosing of DAYBUE, manner of administration, and recommended/prescribed syringe, if applicable.

H

Prescribers must sign this section for the prescription form to be valid. Stamp signatures are not allowed.

Completing Page 3

Patient/Parent/Legal Guardian HIPAA Authorization

The image shows a form titled "PRESCRIPTION AND ENROLLMENT FORM" with logos for Daybue (trofinetide) and acadia connect. At the top, there are fields for "Patient's Name:" and "Date of Birth (MM/DD/YYYY):". Below this is a purple header for "8 PATIENT/PARENT/LEGAL GUARDIAN HIPAA AUTHORIZATION (Please read and sign below if you agree.)". The main body of the form contains several paragraphs of text regarding authorization of healthcare providers and Acadia Connect to use and disclose Protected Health Information (PHI). It includes sections for authorizing Acadia to use PHI for third parties, authorizing Acadia to disclose PHI to other providers, and authorizing Acadia to discuss care coordination with family members. At the bottom of the text area, there are fields for "Authorized Representative(s) (please print):" with sub-fields for "Name:" and "Relationship to Patient:". Below that is a "Sign Here" button and fields for "Patient/Parent/Legal Guardian:" and "Date:". A dark purple box at the bottom of the form contains the submission instructions: "Please submit completed enrollment form via fax to 1-888-385-2748 or email to DAYBUE@AcadiaConnect.com". The footer includes copyright information for Acadia Pharmaceuticals Inc. and the Acadia logo.

I

Include the patient's name and DOB at the top of every page.

J

The parent/legal guardian authorization statement includes consent to share the patient's health information with select parties and for enrollment in Acadia Connect.

Parents/legal guardians can provide consent using the **DAYBUE Patient Consent Form** or on the **DAYBUE Prescription and Enrollment Form**, which your office will submit to Acadia Connect.

Visit AcadiaConnect.com
to download a copy of the DAYBUE Prescription and Enrollment Form